Cargando…

The Persistence of Hepatitis C Virus Infection in Hepatocytes Promotes Hepatocellular Carcinoma Progression by Pro-Inflammatory Interluekin-8 Expression

Background: A large amount of epidemiological evidence indicates that persistent HCV infection is the main risk factor for HCC. We aimed to study the effects of persistent HCV infection on the interaction of the virus and host cell to identify cancer gene profiles. Methods: Next-generation sequencin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shabangu, Ciniso Sylvester, Siphepho, Phumelele Yvonne, Li, Chia-Yang, Cheng, Wei-Chung, Lu, Ming-Ying, Huang, Chung-Feng, Yeh, Ming-Lun, Dai, Chia-Yen, Huang, Jee-Fu, Chuang, Wan-Long, Lin, Zu-Yau, Yu, Ming-Lung, Wang, Shu-Chi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533125/ https://www.ncbi.nlm.nih.gov/pubmed/34680563 http://dx.doi.org/10.3390/biomedicines9101446

Ejemplares similares

The Impact of Steatosis on Chronic Hepatitis C Progression and Response to Antiviral Treatments
por: Siphepho, Phumelele Yvonne, et al.
Publicado: (2021)

The Prevalence and Serological Association of Hepatitis D Virus Genotypes in Taiwan
por: Joseph, Keva, et al.
Publicado: (2021)

Liquid Biopsy for the Diagnosis of Viral Hepatitis, Fatty Liver Steatosis, and Alcoholic Liver Diseases
por: Shabangu, Ciniso Sylvester, et al.
Publicado: (2020)

Dose Consideration of Lenvatinib’s Anti-Cancer Effect on Hepatocellular Carcinoma and the Potential Benefit of Combined Colchicine Therapy
por: Lin, Zu-Yau, et al.
Publicado: (2023)

The impact of an additional extra-hepatic primary malignancy on the outcomes of patients with hepatocellular carcinoma
por: Yeh, Ming-Lun, et al.
Publicado: (2017)

Interluekin-35 in Asthma and Its Potential as an Effective Therapeutic Agent
por: Gao, Peng, et al.
Publicado: (2017)

Tolloid-like 1 genetic variants determine fibrosis regression in chronic hepatitis C patients with curative antivirals
por: Huang, Chung-Feng, et al.
Publicado: (2018)

Pegylated-Interferon Alpha Therapy for Treatment-Experienced Chronic Hepatitis B Patients
por: Yeh, Ming-Lun, et al.
Publicado: (2015)

Association of hyperuricemia with disease severity in chronic hepatitis C patients
por: Jang, Tyng-Yuan, et al.
Publicado: (2018)

The effect of antiviral therapy on serum lipid profiles in chronic hepatitis C
por: Batsaikhan, Batbold, et al.
Publicado: (2018)

Pretreatment glucose status determines HCC development in HCV patients with mild liver disease after curative antiviral therapy
por: Huang, Chung-Feng, et al.
Publicado: (2016)

Lower protein expression levels of MHC class I chain-related gene A in hepatocellular carcinoma are at high risk of recurrence after surgical resection
por: Huang, Chung-Feng, et al.
Publicado: (2018)

Persistent cryoglobulinemia after antiviral treatment is associated with advanced fibrosis in chronic hepatitis C patients
por: Batsaikhan, Batbold, et al.
Publicado: (2022)

PNPLA3 genetic variants determine hepatic steatosis in non-obese chronic hepatitis C patients
por: Huang, Chung-Feng, et al.
Publicado: (2015)

Hyperuricemia Inversely Correlates with Disease Severity in Taiwanese Nonalcoholic Steatohepatitis Patients
por: Huang, Jee-Fu, et al.
Publicado: (2015)

Post-treatment alpha fetoprotein and platelets predict hepatocellular carcinoma development in dual-infected hepatitis B and C patients after eradication of hepatitis C
por: Yeh, Ming-Lun, et al.
Publicado: (2018)

Equal treatment efficacy of direct-acting antivirals in patients with chronic hepatitis C and hepatocellular carcinoma? A prospective cohort study
por: Huang, Chung-Feng, et al.
Publicado: (2019)

Interactions of a PPARGC1A Variant and a PNPLA3 Variant Affect Nonalcoholic Steatohepatitis in Severely Obese Taiwanese Patients
por: Tai, Chi-Ming, et al.
Publicado: (2016)

Virological Predictors of Response to Retreatment in Hepatitis C Genotype 2 Infected Patients
por: Huang, Chung-Feng, et al.
Publicado: (2013)

Wisteria floribunda agglutinin-positive Mac-2-binding protein in the prediction of disease severity in chronic hepatitis B patients
por: Yeh, Ming-Lun, et al.
Publicado: (2019)

Personalized Therapy of Chronic Hepatitis C and B Dually Infected Patients With Pegylated Interferon Plus Ribavirin: A Randomized Study
por: Yeh, Ming-Lun, et al.
Publicado: (2015)

Role of IL-28B genetic variants in HCV-related liver disease severity in patients with different viral genotypes
por: Huang, Ching-I, et al.
Publicado: (2018)

Towards a safe hospital: hepatitis C in-hospital micro-elimination program (HCV-HELP study)
por: Huang, Jee-Fu, et al.
Publicado: (2021)

Discrepancy between Serological and Virological Analysis of Viral Hepatitis in Hemodialysis Patients
por: Chang, Jer-Ming, et al.
Publicado: (2014)

Less liver fibrosis marker increment in overweight chronic hepatitis B patients observed by age-adjusted Fibrosis-4 Index
por: Liu, Ta-Wei, et al.
Publicado: (2020)

Abbott RealTime HBV Assay Is More Sensitive in Detection of Low Viral Load and Little Impacted by Drug Resistant Mutation in Chronic Hepatitis B Patients under Nucleot(s)ide Analogues Therapy
por: Yeh, Ming-Lun, et al.
Publicado: (2014)

Genetic association between interluekin-4 rs2243250 polymorphism and gastric cancer susceptibility: evidence based on a meta-analysis
por: Zhang, Chi, et al.
Publicado: (2016)

Viral Interference Between Dengue Virus and Hepatitis C Virus Infections
por: Liang, Po-Cheng, et al.
Publicado: (2020)

Itemization difference of patient-reported outcome in patients with chronic liver disease
por: Lin, Ming-Chieh, et al.
Publicado: (2022)

Scaling up the in-hospital hepatitis C virus care cascade in Taiwan
por: Huang, Chung-Feng, et al.
Publicado: (2021)

Elevated on-treatment levels of serum IFN-gamma is associated with treatment failure of peginterferon plus ribavirin therapy for chronic hepatitis C
por: Lu, Ming-Ying, et al.
Publicado: (2016)

Genetics Variants and Serum Levels of MHC Class I Chain-related A in Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis C Patients Post Antiviral Treatment
por: Huang, Chung-Feng, et al.
Publicado: (2016)

Corrigendum to “Genetics Variants and Serum Levels of MHC Class I Chain-related A in Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis C Patients Post Antiviral Treatment” [EBioMedicine 15 (2017) 81–89]
por: Huang, Chung-Feng, et al.
Publicado: (2017)

Diversity of the association of serum levels and genetic variants of MHC class I polypeptide-related chain A with liver fibrosis in chronic hepatitis C
por: Huang, Chung-Feng, et al.
Publicado: (2017)

Clusters of Circulating let-7 Family Tumor Suppressors Are Associated with Clinical Characteristics of Chronic Hepatitis C
por: Tsai, Yi-Shan, et al.
Publicado: (2020)

Circulating Let-7 Family Members as Non-Invasive Biomarkers for Predicting Hepatocellular Carcinoma Risk after Antiviral Treatment among Chronic Hepatitis C Patients
por: Tsai, Yi-Shan, et al.
Publicado: (2022)

Significant down-regulation of growth hormone receptor expression revealed as a new unfavorable prognostic factor in hepatitis C virus-related hepatocellular carcinoma
por: Lin, Ching-Chih, et al.
Publicado: (2021)

Different profiles of neurocognitive impairment in patients with hepatitis B and C virus infections
por: Tan, Chun-Hsiang, et al.
Publicado: (2022)

Huge Gap Between Clinical Efficacy and Community Effectiveness in the Treatment of Chronic Hepatitis C: A Nationwide Survey in Taiwan
por: Yu, Ming-Lung, et al.
Publicado: (2015)

Anti-HCV antibody titer highly predicts HCV viremia in patients with hepatitis B virus dual-infection
por: Liu, Hung-Yin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tvl4goa5be5df84ul91tar6ue5